Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar 78taxs (37.49) Submitted: 9/18/2012 6:32:58 PM : Outperform Start Price: $4.95 DVAX Score: -91.90

FDA will approve it .

Featured Broker Partners


Advertisement